Get the Stockscreener App
46.55
0.67%
0.31
After Hours:
46.98
0.43
+0.92%
Revolution Medicines Inc stock is traded at $46.55, with a volume of 3.63M.
It is up +0.67% in the last 24 hours and up +32.02% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$46.24
Open:
$46.8
24h Volume:
3.63M
Relative Volume:
1.59
Market Cap:
$8.70B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-12.72
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+14.94%
1M Performance:
+32.02%
6M Performance:
+18.75%
1Y Performance:
+10.91%
1-Day Range:
$45.18
$47.04
1-Week Range:
$39.73
$47.04
52-Week Range:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
46.55 | 7.56B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution’s Daraxonrasib Data Bolster Phase III Case Amid RAS Cancer Push - insights.citeline.com
Goldman Sachs Raises Price Target for RVMD to $73.00, Maintains Buy Rating | RVMD Stock News - GuruFocus
Fred Alger Management LLC Has $4.15 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Stock Skyrockets: What’s Next? - timothysykes.com
Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results - simplywall.st
Adage Capital Partners GP L.L.C. Has $13.93 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Benzinga
Revolution Medicines’ Surging Potential: What’s Happening? - StocksToTrade
Revolution Medicines: Shares Soar On Pancreatic Cancer Study WinI'm Sold (NASDAQ:RVMD) - Seeking Alpha
Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene and more - CNBC
Revolution Medicines announces results from daraxonrasib Phase 1 trials - TipRanks
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Wedbush Raises Price Target on Revolution Medicines to $77 From $73, Keeps Outperform Rating - MarketScreener
Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines - TipRanks
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick - Clinical Trials Arena
Promising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating - TipRanks
Revolution Medicines price target raised to $70 from $67 at Wells Fargo - TipRanks
Cinctive Capital Management LP Sells 23,447 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Trexquant Investment LP Acquires New Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines - TipRanks
Granahan Investment Management LLC Acquires 7,322 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines reports promising pancreatic cancer drug results - Investing.com India
Revolution Medicines reports promising pancreatic cancer drug results By Investing.com - Investing.com South Africa
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - Seeking Alpha
Revolution Medicines Shares Under Pressure Despite Positive News - TipRanks
Revolution Medicines Reports Promising Phase 1 Study Results - TipRanks
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - The Manila Times
Revolution Medicines Reports Promising Long-term Data for Daraxonrasib in Metastatic Pancreatic Cancer and Announces Phase 3 Trial Plans - Quiver Quantitative
Did Truist’s Coverage of RAS Pipeline Just Shift Revolution Medicines’ (RVMD) Investment Narrative? - simplywall.st
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Truist Financial - MarketBeat
Revolution Medicines (RVMD): Assessing Valuation After Truist Highlights Potential of RAS-mutant Cancer Pipeline - Yahoo Finance
How does Revolution Medicines Inc. correlate with NasdaqJuly 2025 Macro Moves & Precise Swing Trade Alerts - Lancaster City Council
Revolution Medicines, Inc. $RVMD Holdings Lifted by Checkpoint Capital L.P. - MarketBeat
Published on: 2025-09-09 05:17:32 - 뉴스영
Support Zone Holds Steady for Revolution Medicines Inc. After Dip2025 Valuation Update & Smart Money Movement Tracker - beatles.ru
Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway? - Yahoo Finance
Revolution Medicines (RVMD): Exploring Valuation After Truist Coverage Highlights Pipeline Potential - simplywall.st
Revolution Medicines (NASDAQ:RVMD) Stock Price Up 5.2%Still a Buy? - MarketBeat
ADAR1 Capital Management LLC Acquires 7,136 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
BVF Inc. IL Boosts Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
What machine learning models say about Revolution Medicines Inc.July 2025 Catalysts & AI Forecast for Swing Trade Picks - Newser
What’s the recovery path for long term holders of Revolution Medicines Inc.July 2025 Breakouts & AI Optimized Trade Strategies - Newser
Will Revolution Medicines Inc. Equity Warrant stock go up soonMarket Movers & High Accuracy Buy Signal Tips - Newser
Institutional scanner results for Revolution Medicines Inc.Portfolio Gains Report & Daily Technical Forecast Reports - Newser
Strategies to average down on Revolution Medicines Inc. Equity Warrant - Newser
Short interest data insights for Revolution Medicines Inc. Equity WarrantMarket Growth Summary & Risk Managed Trade Strategies - Newser
Revolution Medicines stock initiated with Buy rating at Truist Securities By Investing.com - Investing.com Canada
Raymond James Financial Inc. Reduces Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
What analysts say about Revolution Medicines Inc. stockMarket Trend Review & High Return Stock Watch Alerts - خودرو بانک
Is Revolution Medicines Inc. exposed to currency risksTrade Entry Summary & Daily Stock Trend Reports - خودرو بانک
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):